|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 7
2021
Brake, Lindsey H. M. te; de Jager, Veronique; Narunsky, Kim; Vanker, Naadira; Svensson, Elin M.; Phillips, Patrick P. J.; Gillespie, Stephen H.; Heinrich, Norbert; Hoelscher, Michael; Dawson, Rodney; Diacon, Andreas H.; Aamoutse, Rob E. und Boeree, Martin J.
(2021):
Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin.
In: European Respiratory Journal, Bd. 58, Nr. 1, 2000955
Zhang, Nan; Savic, Radojka M.; Boeree, Martin J.; Peloquin, Charles A.; Weiner, Marc; Heinrich, Norbert; Bliven-Sizemore, Erin; Phillips, Patrick P. J.; Hoelscher, Michael; Whitworth, William; Morlock, Glenn; Posey, James; Stout, Jason E.; Mac Kenzie, William; Aarnoutse, Robert und Dooley, Kelly E.
(2021):
Optimising pyrazinamide for the treatment of tuberculosis.
In: European Respiratory Journal, Bd. 58, Nr. 1, 2002013
2020
Sabiiti, Wilber; Azam, Khalide; Farmer, Eoghan Charles William; Kuchaka, Davis; Mtafya, Bariki; Bowness, Ruth; Oravcova, Katarina; Honeyborne, Isobella; Evangelopoulos, Dimitrios; McHugh, Timothy Daniel; Khosa, Celso; Rachow, Andrea; Heinrich, Norbert; Kampira, Elizabeth; Davies, Geraint; Bhatt, Nilesh; Ntinginya, Elias N.; Viegas, Sofia; Jani, Ilesh; Kamdolozi, Mercy; Mdolo, Aaron; Khonga, Margaret; Boeree, Martin J.; Phillips, Patrick P. J.; Sloan, Derek; Hoelscher, Michael; Kibiki, Gibson und Gillespie, Stephen H.
(2020):
Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay.
In: Thorax, Bd. 75, Nr. 7: S. 606-608
[PDF, 703kB]
2018
Svensson, Elin M.; Svensson, Robin J.; te Brake, Lindsey H. M.; Böree, Martin J.; Heinrich, Norbert; Konsten, Sarah; Churchyard, Gavin; Dawson, Rodney; Diacon, Andreas H.; Kibiki, Gibson S.; Minja, Lilian T.; Ntingiya, Nyanda E.; Saone, Ian; Gillespie, Stephen H.; Hölscher, Michael; Phillips, Patrick P. J.; Simonsson, Ulrika S. H. und Aarnoutse, Rob
(2018):
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
In: Clinical Infectious Diseases, Bd. 67, Nr. 1: S. 34-41
2017
Boeree, Martin J.; Heinrich, Norbert; Aarnoutse, Rob; Diacon, Andreas H.; Dawson, Rodney; Rehal, Sunita; Kibiki, Gibson S.; Churchyard, Gavin; Sanne, Ian; Ntinginya, Nyanda E.; Minja, Lilian T.; Hunt, Robert D.; Charalambous, Salome; Hanekom, Madeleine; Semvua, Hadija H.; Mpagama, Stellah G.; Manyama, Christina; Mtafya, Bariki; Reither, Klaus; Wallis, Robert S.; Venter, Amour; Narunsky, Kim; Mekota, Anka; Henne, Sonja; Colbers, Angela; Plemper van Balen, Georgette; Gillespie, Stephen H.; Phillips, Patrick P. J. und Hölscher, Michael
(2017):
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
In: Lancet infectious Diseases, Bd. 17, Nr. 1: S. 39-49
2016
Phillips, Patrick P. J.; Dooley, Kelly E.; Gillespie, Stephen H.; Heinrich, Norbert; Stout, Jason E.; Nahid, Payam; Diacon, Andreas H.; Aarnoutse, Rob E.; Kibiki, Gibson S.; Boeree, Martin J. und Hoelscher, Michael
(2016):
A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).
In: BMC Medicine
14:51
[PDF, 2MB]
Dooley, Kelly E.; Phillips, Patrick P. J.; Nahid, Payam und Hölscher, Michael
(2016):
Challenges in the clinical assessment of novel tuberculosis drugs.
In: Advanced Drug Delivery Reviews, Bd. 102: S. 116-122